This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Other. Active years: 2016.
Company Filing History:
1 out of 834,453 Years Active: 2016
Title: Innovations of Shanmin Yang in Pulmonary Fibrosis Treatment
Introduction
Shanmin Yang is an accomplished inventor based in Gainesville, FL (US). He has made significant contributions to the field of medicine, particularly in the treatment of pulmonary fibrosis. His innovative approach focuses on the use of specific compounds to address this challenging condition.
Latest Patents
Shanmin Yang holds a patent for the "Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis." This invention pertains to novel uses of glycyrrhetinic acid (GA), glycyrrhizic acid (GLA), and related compounds specifically for the prevention and treatment of irradiation-induced pulmonary fibrosis. The patent also encompasses therapeutic uses of prodrugs, metabolites, derivatives, and salts of these compounds. Furthermore, it provides for pharmaceutical compositions that can be combined with a pharmaceutically acceptable carrier.
Career Highlights
Throughout his career, Shanmin Yang has worked with various companies, including notable collaborations that have enhanced his research and development efforts. His work has led to advancements in therapeutic applications that could significantly impact patient care.
Collaborations
Shanmin Yang has collaborated with esteemed colleagues such as Jianhua Xu and Lurong Zhang. These partnerships have fostered a collaborative environment that promotes innovation and the sharing of ideas in the field of pulmonary fibrosis treatment.
Conclusion
Shanmin Yang's contributions to the treatment of pulmonary fibrosis through his innovative use of glycyrrhetinic acid and glycyrrhizic acid highlight the importance of research and development in medicine. His work continues to pave the way for new therapeutic options for patients suffering from this condition.